Relay Therapeutics (RLAY) Liabilities and Shareholders Equity (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $699.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 12.48% year-over-year to $699.6 million in Q1 2026; TTM through Mar 2026 was $2.7 billion, a 19.37% decrease from a year earlier, with the FY2025 full-year figure at $621.3 million, down 28.69% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $699.6 million, up from $621.3 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RLAY reached as high as $1.2 billion in Q3 2022 and fell as low as $621.3 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $870.2 million across 5 years, with a median of $871.3 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity surged 176443.5% in 2022 and retreated 28.69% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then declined by 23.26% to $844.0 million in 2023, then rose by 3.24% to $871.3 million in 2024, then slipped by 28.69% to $621.3 million in 2025, then rose by 12.6% to $699.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $699.6 million in Q1 2026, $621.3 million in Q4 2025, and $670.0 million in Q3 2025.